Caladrius Biosciences, Inc. (CLBS)

Trade CLBS now with
9/14/2022 8:30:59 AM Caladrius Biosciences Announces Approval Of Merger And Name Change To Lisata Therapeutics
8/2/2022 8:47:25 AM Caladrius Biosciences Completes Enrollment In Phase 1b Study Of CLBS201 For Diabetic Kidney Disease
5/19/2022 8:15:14 AM Caladrius Biosciences Announces IDMC Recommendation To Advance CLBS201 Trial For Diabetic Kidney Disease
3/8/2021 8:12:08 AM Caladrius Biosciences Reports Orphan Drug Designation For CLBS12 For Treatment Of Buerger’s Disease
5/14/2019 6:43:19 AM WBB Securities Starts Caladrius Biosciences, Inc. (CLBS) At Speculative Buy With $6.75 Price Target